Antiproteinuric Effect of Cilnidipine in Hypertensive Japanese Treated with Renin-Angiotensin-System Inhibitors - A Multicenter, Open, Randomized Trial Using 24-Hour Urine Collection

REFERENCES

• Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988;2:530–533.
   PubMed Web of Science ®Google Scholar
• Bigazzi R, Bianchi S, Baldari D, Compese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998;16: 1325–1333.
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A, Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study). J Hypertens 2006;24:541–548.
   PubMed Web of Science ®Google Scholar
• Irie F, Iso H, Sairenchi T, The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006;69:1264–1271.
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997;51:2–15 (Review).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329: 1456–1462.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med.2001; 345:870–878.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–2572.
   PubMed Web of Science ®Google Scholar
• Guideline Subcommittee. Japanese society of hypertension guidelines for the management of hypertension (JSH 2004) Hypertens Res 2006;29(suppl):S1–S105.
   PubMedGoogle Scholar
• Hirning LD, Fox AP, McCleskey EW, Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons. Science 1988;239:57–61.
   PubMed Web of Science ®Google Scholar
• Fogo AB. Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int Suppl 2000;75:S15–21 (Review).
   PubMedGoogle Scholar
• DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77:75–197 (Review).
   PubMed Web of Science ®Google Scholar
• Zhou X, Ono H, Ono Y, Frohlich ED. N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens 2002;20:993–1000.
   PubMed Web of Science ®Google Scholar
• Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005;101:1–13.
   Google Scholar
• Rose GW, Kanno Y, Ikebukuro H, Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001;24:377–383.
   PubMed Web of Science ®Google Scholar
• Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27:379–385.
   PubMed Web of Science ®Google Scholar
• Fujita T, Ando K, Nishimura H, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007;72:1543–1549.
   PubMed Web of Science ®Google Scholar
• Tsuchihashi T, Ueno M, Tominaga M, Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine. Clin Exp Hypertens 2005;27:583–591.
   PubMed Web of Science ®Google Scholar
• Tochikubo O, Uneda S, Kaneko Y. Simple portable device for sampling a whole day's urine and its application to hypertensive outpatients. Hypertension 1983;5:270–274.
   PubMed Web of Science ®Google Scholar
• Peterson JC, Adler S, Burkart JM, Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123: 754–762.
   PubMed Web of Science ®Google Scholar
• Oike M, Inoue Y, Kitamura K, Kuriyama H. Dual action of FRC8653, a novel dihydropyridine derivative, on the Ba2+ current recorded from the rabbit basilar artery. Circ Res 1990;67: 993–1006.
   PubMed Web of Science ®Google Scholar
• Fujii S, Kameyama K, Hosono M, Hayashi Y, Kitamura K. Effect of cilnidipine, a novel dihydropyridine Ca2+-channel antagonist, on N-type Ca2+ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1997;280:1184–1191.
   PubMed Web of Science ®Google Scholar
• Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N. Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br J Pharmacol 1997;122:37–42.
   PubMed Web of Science ®Google Scholar
• Loutzenhiser R, Hayashi K, Epstein M. Divergent effects of KCl-induced depolarization on afferent and efferent arterioles. Am J Physiol 1989;257:F561–564.
   PubMed Web of Science ®Google Scholar
• Fujii S, Hosono M, Hayashi Y, Kimura K. Cilnidipine, a novel dihydropyridine derivative, dilates glomerular efferent arterioles by N-type Ca2+-channel blockade. J Hypertens 1998;16 (suppl 2):S182 (abstract).
   Google Scholar
• Sugiura T, Imai E, Moriyama T, Horio M, Hori M. Calcium channel blockers inhibit proliferation and matrix production in rat mesangial cells: possible mechanism of suppression of AP-1 and CREB activities. Nephron 2000;85:71–80.
   PubMed Web of Science ®Google Scholar
• Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30–48.
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547–553.
   PubMed Web of Science ®Google Scholar
• Minami J, Ishimitsu T, Kawano Y, Numabe A, Matsuoka H. Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J Cardiovasc Pharmacol 1998;32:331–336.
   PubMed Web of Science ®Google Scholar
• The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857–1863.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49:12–26 (Review).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Remuzzi G; GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003;63: 2254–2261.
   PubMed Web of Science ®Google Scholar